Current main theme: Development of nanotherapeutics for the treatment of brain tumors

Current treatments against brain tumors have very low efficacy due to the incapacity of most drugs to cross the blood-brain barrier (BBB) and to eliminate cells resilient to traditional chemotherapies.


Our team aims to develop bio- and nano-therapeutics capable of overcoming the BBB and of eliminating all tumor cells, in primary and metastatic brain tumors. We are interested in developing ligands to target the therapeutic systems and to cross the BBB. We also aim to engineer polymeric coatings to enhance the stability of the nanocarriers for gene delivery.


Distinct aspects of this ambitious project are funded by "La Caixa", the Marie Sklodowska-Curie Actions (EU), the Spanish Ministry of Science, the "Asociación Española Contra el Cáncer" (AECC), and AGAUR.

Development of conditionally-activated biotherapeutics

We are engineering new strategies to render antibodies responsive to stimuli and enhance the selectivity of bio- and nano-therapeutics.

Generation of new protease-resistant peptide therapeutics and targeting ligands

Our team is developing new efficient peptides that enable the transport of therapeutics across the blood-brain barrier. We are also working on therapeutic peptides for other applications.

Phage display engineering

We aim to develop new peptide and protein therapeutics via directed evolution by expanding the chemical diversity encoded into phage displayed molecules.

Peptide-based smart coatings and gene delivery systems

We utilize peptides to construct environmentally-sensitive nanocarriers and coatings. 

Protein Targeted Therapeutics